Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study
Open accessThe DOI matches its Crossref record; 54 of the 58 references it cites were found in a registry or an index.
Abstract
Background: Identifying reliable predictors of long-term weight loss (LTWL) could lead to improved weight management. Objective: To identify some predictors of LTWL. Design: The DPP (Diabetes Prevention Program) was a randomized controlled trial that compared weight loss with metformin, intensive lifestyle intervention (ILS), or placebo. Its Outcomes Study (DPPOS) observed patients after the masked treatment phase ended. (ClinicalTrials.gov: NCT00004992 and NCT00038727). Setting: 27 DPP and DPPOS clinics. Participants: Of the 3234 randomly assigned participants, 1066 lost at least 5% of baseline weight in the first year and were followed for 15 years. Measurements: Treatment assignment, personal characteristics, and weight. Results: After 1 year, 289 (28.5%) participants in the metformin group, 640 (62.6%) in the ILS group, and 137 (13.4%) in the placebo group had lost at least 5% of their weight. After the masked treatment phase ended, the mean weight loss relative to baseline that was maintained between years 6 and 15 was 6.2% (95% CI, 5.2% to 7.2%) in the metformin group, 3.7% (CI, 3.1% to 4.4%) in the ILS group, and 2.8% (CI, 1.3% to 4.4%) in the placebo group. Independent predictors of LTWL included greater weight loss in the first year in all groups, older age and continued metformin use in the metformin group, older age and absence of either diabetes or a family history of diabetes in the ILS group, and higher fasting plasma glucose levels at baseline in the placebo group. Limitation: Post hoc analysis; examination of nonrandomized subsets of randomized groups after year 1. Conclusion: Among persons with weight loss of at least 5% after 1 year, those originally randomly assigned to metformin had the greatest loss during years 6 to 15. Older age and the amount of weight initially lost were the most consistent predictors of LTWL maintenance. Primary Funding Source: National Institutes of Health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mean weight loss at 15-year follow-up was 6.2% (95% CI, 5.2%-7.2%) for metformin, 3.7% (95% CI, 3.1%-4.4%) for intensive lifestyle intervention, and 2.8% for placebo (95% CI, 1.3%-4.4%).93”
From Obesity Management in Adults: A Review (2023) · cites this paper as [93]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Doses of metformin greater than 1500 mg are associated with the greatest weight loss.93,94”
From Obesity Management in Adults: A Review (2023) · cites this paper as [93]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“12 weeks of treatment with licogliflozin led to a numerically greater reduction in liver lipid content, body weight (4.2 %) and HbA1c (1 %) compared to RCTs with sole SGLT2I treatment (Table 1) [161,163].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [161]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 3×
“Randomized controlled trials (RCTs) have shown efficacy of metformin, intensive lifestyle intervention (ILS), or both in preventing or delaying onset of T2D among high-risk persons with overweight and obesity (2, 3).”
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
Longitudinal Data Analysis for Discrete and Continuous Outcomes
Zeger, S. L., & Liang, K.-Y. (1986) · Biometrics · doi:10.2307/2531248 · Cited by 7,764 · cited 1×
“Second, we used GEE models (15, 16) to examine potential predictors of LTWL across all follow-up years.”
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Models for Longitudinal Data: A Generalized Estimating Equation Approach
Zeger, S. L., Liang, K.-Y., & Albert, P. S. (1988) · Biometrics · doi:10.2307/2531734 · Cited by 4,505 · cited 1×
“Second, we used GEE models (15, 16) to examine potential predictors of LTWL across all follow-up years.”
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
The mechanisms of action of metformin
Rena, G., Hardie, D. G., & Pearson, E. R. (2017) · Diabetologia · doi:10.1007/s00125-017-4342-z · Cited by 2,287 · cited 1×
“Its beneficial effects include inhibition of gluconeogenesis with a consequent decrease in hepatic glucose output and increased insulin sensitivity, increased glucose utilization in the gut and enhanced insulin sensitivity in skeletal muscle (25, 26), and effects on the gut microbiota and the immune system (27).”
Research works printed but not linked: 1
- Diggle PJ, Liang K-Y, Zeger SL. Analysis of longitudinal data. New York: Oxford University Press; 1994.
Cited by
Obesity Management in Adults: A Review
Elmaleh-Sachs, A., Schwartz, J. L., Bramante, C. T., Nicklas, J. M., Gudzune, K. A., & Jay, M. (2023) · JAMA · doi:10.1001/jama.2023.19897 · Cited by 813
Type 2 diabetes mellitus in older adults: clinical considerations and management
Bellary, S., Kyrou, I., Brown, J. E., & Bailey, C. J. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00512-2 · Cited by 639
GDF15 mediates the effects of metformin on body weight and energy balance
Coll, A. P., Chen, M., Taskar, P., Rimmington, D., Patel, S., Tadross, J. A., Cimino, I., Yang, M., Welsh, P., Virtue, S., et al. (2020) · Nature · doi:10.1038/s41586-019-1911-y · Cited by 584
Chung, W. K., Erion, K., Florez, J. C., Hattersley, A. T., Hivert, M.-F., Lee, C. G., McCarthy, M. I., Nolan, J. J., Norris, J. M., Pearson, E. R., et al. (2020) · Diabetes Care · doi:10.2337/dci20-0022 · Cited by 400
Self-citationSarcopenic obesity: Emerging mechanisms and therapeutic potential
Axelrod, C. L., Dantas, W. S., & Kirwan, J. P. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155639 · Cited by 204
“Metformin attenuates weight gain and results in modest weight reduction over long term administration in humans by restricting food intake and enhancing peripheral insulin sensitivity [130,131].”
BackgroundChung, W. K., Erion, K., Florez, J. C., Hattersley, A. T., Hivert, M.-F., Lee, C. G., McCarthy, M. I., Nolan, J. J., Norris, J. M., Pearson, E. R., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05181-w · Cited by 203
Self-citationMetformin and cancer hallmarks: shedding new lights on therapeutic repurposing
Hua, Y., Zheng, Y., Yao, Y., Jia, R., Ge, S., & Zhuang, A. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04263-8 · Cited by 199
“Over time, the benefits associated with repurposing metformin for several challenging diseases, including obesity [3], cardiovascular diseases [4, 5], liver diseases [6], renal diseases [7], aging-related diseases [8], and cancers [9] have been shown.”
BackgroundObesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169
Bray, G. A., & Ryan, D. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14200 · Cited by 148
Waters, D. L., Aguirre, L., Gurney, B., Sinacore, D. R., Fowler, K., Gregori, G., Armamento-Villareal, R., Qualls, C., & Villareal, D. T. (2022) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glab111 · Cited by 99
“Findings from other studies also suggest that older adults may be more successful in achieving long-term weight loss than younger adults (49,50).”
ResultJonas, D. E., Crotty, K., Yun, J. D. Y., Middleton, J. C., Feltner, C., Taylor-Phillips, S., Barclay, C., Dotson, A., Baker, C., Balio, C. P., et al. (2021) · JAMA · doi:10.1001/jama.2021.10403 · Cited by 96
The Many Faces of Obesity and Its Influence on Breast Cancer Risk
Agurs‐Collins, T., Ross, S. A., & Dunn, B. K. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00765 · Cited by 108
“4% in the placebo group had achieved this goal (161).”
BackgroundNdumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Lac-Phe mediates the effects of metformin on food intake and body weight
Xiao, S., Li, V. L., Lyu, X., Chen, X., Wei, W., Abbasi, F., Knowles, J. W., Tung, A. S.-H., Deng, S., Tiwari, G., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-00999-9 · Cited by 91
Zhang, Y., Li, D., Zhu, Z., Chen, S., Lu, M., Cao, P., Chen, T., Li, S., Xue, S., Zhang, Y., et al. (2022) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2022.06.010 · Cited by 81
Kaneto, H., Kimura, T., Obata, A., Shimoda, M., & Kaku, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052596 · Cited by 90
Metformin selectively dampens the acute inflammatory response through an AMPK-dependent mechanism
Postler, T. S., Peng, V., Bhatt, D. M., & Ghosh, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-97441-x · Cited by 75
Sampson, M., Clark, A., Bachmann, M. O., Garner, N. J., Irvine, L., Howe, A. C., Greaves, C. J., Auckland, S., Smith, J. R., Turner, J. J. O., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.5938 · Cited by 83
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 153
Effectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66
Metformin for diabetes prevention: update of the evidence base
Gottwald‐Hostalek, U., & Campbell, I. W. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1955667 · Cited by 81
Gilbert, O., Gulati, M., Gluckman, T. J., Kittleson, M. M., Rikhi, R., Saseen, J. J., & Tchang, B. G. (2025) · JACC · doi:10.1016/j.jacc.2025.05.024 · Cited by 65
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Haddad, F., Dokmak, G., Bader, M., & Karaman, R. (2023) · Life · doi:10.3390/life13041012 · Cited by 79
“Those who lost at least 5% of their starting body weight underwent surveillance for more than 15 years, according to the DPP observational study [23].”
BackgroundMethodNutritional Strategies for the Management of Type 2 Diabetes Mellitus: A Narrative Review
Minari, T. P., Tácito, L. H. B., Yugar, L. B. T., Ferreira‐Melo, S. E., Manzano, C. F., Pires, A. C., Moreno, H., Vilela-Martin, J. F., Cosenso‐Martin, L. N., & Yugar‐Toledo, J. C. (2023) · Nutrients · doi:10.3390/nu15245096 · Cited by 103
Dietary Strategies for Weight Loss Maintenance
van Baak, M. A., & Mariman, E. C. M. (2019) · Nutrients · doi:10.3390/nu11081916 · Cited by 57
Cancer and Obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
Lazarus, E., & Bays, H. E. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100026 · Cited by 55
“Metformin, a biguanide medication used to treat type 2 diabetes mellitus, reduces hyperinsulinemia [128,129].”
BackgroundPrecision medicine in adult and pediatric obesity: a clinical perspective
Bomberg, E. M., Ryder, J. R., Brundage, R. C., Straka, R. J., Fox, C. K., Gross, A. C., Oberle, M. M., Bramante, C. T., Sibley, S. D., & Kelly, A. S. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819863022 · Cited by 52
Precision nutrition in diabetes: when population-based dietary advice gets personal
Merino, J. (2022) · Diabetologia · doi:10.1007/s00125-022-05721-6 · Cited by 58
“To identify factors associated with long-term weight-loss success, a post hoc analysis of the Diabetes Prevention Program Outcomes Study showed that losing more than 5% of body weight during the first year of the intervention, achieved either by an intensive lifestyle intervention or metformin, was an independent pred…”
ResultMolecular mechanisms of action of metformin: latest advances and therapeutic implications
Zhu, H., Jia, Z., Li, Y. R., & Danelisen, I. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01051-y · Cited by 61
“It is well established that metformin treatment is associated with weight loss in diabetic and non-diabetic people [70–72].”
BackgroundASN Kidney Health Guidance on the Management of Obesity in Persons Living with Kidney Diseases
Ikizler, T. A., Kramer, H., Beddhu, S., Chang, A. R., Friedman, A. N., Harhay, M. N., Jimenez, E. Y., Kistler, B. M., Kukla, A., Larson, K., et al. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000512 · Cited by 44
Look AHEAD Research Group, Chao, A. M., Wadden, T. A., Berkowitz, R. I., Blackburn, G., Bolin, P., Clark, J. M., Coday, M., Curtis, J. M., Delahanty, L. M., et al. (2020) · Obesity · doi:10.1002/oby.22769 · Cited by 40
Self-citationSzczerbiński, Ł., & Florez, J. C. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00232-2 · Cited by 45
Type 2 Diabetes Prevention Focused on Normalization of Glycemia: A Two-Year Pilot Study
McKenzie, A. L., Athinarayanan, S. J., McCue, J. J., Adams, R. N., Keyes, M., McCarter, J. P., Volek, J. S., Phinney, S. D., & Hallberg, S. J. (2021) · Nutrients · doi:10.3390/nu13030749 · Cited by 37
“Greater weight loss in the first year was associated with longterm weight loss maintenance of 5% or more, regardless of initial treatment, throughout the DPP and DPPOS [26].”
BackgroundInfluentialProgesterone Attenuates SIRT1-Deficiency-Mediated Pre-Eclampsia
Pei, J., Liu, Z., Wang, C., Chu, N., Liu, L., Tang, Y., Liu, H., Xiang, Q., Cheng, H., Li, M., et al. (2022) · Biomolecules · doi:10.3390/biom12030422 · Cited by 37
“We concluded that this might be related to the weight-reducing effect of metformin [58].”
BackgroundDiet quality, weight loss, and diabetes incidence in the Diabetes Prevention Program (DPP)
Allaire, B. T., Tjaden, A. H., Venditti, E. M., Apolzan, J. W., Dabelea, D., Delahanty, L. M., Edelstein, S. L., Hoskin, M. A., Temple, K. A., Wylie‐Rosett, J., et al. (2020) · BMC Nutrition · doi:10.1186/s40795-020-00400-4 · Cited by 40
“A 5% weight loss threshold was chosen because it is a commonly used threshold in previous studies, including DPP [25].”
MethodSelf-citationBajetto, A., Pattarozzi, A., Sirito, R., Barbieri, F., & Florio, T. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111078 · Cited by 35
Reframing prediabetes: A call for better risk stratification and intervention
Kim, S. H. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13786 · Cited by 34
“Only 50% of individuals randomized to the intensive lifestyle arm met this goal, and only 38% were able to sustain this degree of weight loss by the end of the study [38, 83].”
BackgroundObesity Management in the Primary Prevention of Hepatocellular Carcinoma
Zunica, E. R. M., Heintz, E. C., Axelrod, C. L., & Kirwan, J. P. (2022) · Cancers · doi:10.3390/cancers14164051 · Cited by 32
Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits
Yip, J., Chiang, G. S. H., Lee, I. C. J., Lehming-Teo, R., Dai, K., Dongol, L., Wang, L. Y.-T., Teo, D. W. X., Seah, G. T., & Lehming, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26010364 · Cited by 31
“Gliclazide has proven effective in promoting weight loss or preventing weight gain in patients with non-insulin-dependent diabetes.”
Chukir, T., Mandel, L., Tchang, B. G., Al-Mulla, N. A., Igel, L. I., Kumar, R. B., Waitman, J. A., Aronne, L. J., & Shukla, A. P. (2020) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2020.12.005 · Cited by 29
Oser, T. K., Cucuzzella, M. T., Stasinopoulos, M., MONCRIEF, M. A., McCall, A. L., & Cox, D. J. (2022) · JMIR Diabetes · doi:10.2196/34465 · Cited by 27
“While the American Diabetes Association recommends weight loss of at least 7% and at least 150 minutes per week of moderate to vigorous physical activity to help manage T2D [2], up to 15% of these patients do not need to lose weight [3], while others are either unwilling or unable to lose weight and to maintain weight…”
BackgroundBensignor, M. O., Bomberg, E. M., Bramante, C. T., Divyalasya, T. V. S., Hale, P. M., Ramesh, C. K., Rudser, K. D., & Kelly, A. S. (2021) · Pediatric Obesity · doi:10.1111/ijpo.12778 · Cited by 34
“42,43 However, evidence suggests that metformin is not associated with meaningful weight reduction, 8,9,44,45 and the Treatment Options for T2D for Adolescents and Youth (TODAY) study demonstrated that the median time to treatment failure (defined as HbA 1c ≥ 8.0% [64 mmol/mol] over 6 months or…”
InfluentialThe Final Frontier in Diabetes Care: Implementing Research in Real-World Practice
Green, J. B., Crowley, M. J., Sathish, T., Maruthur, N. M., & Oldenburg, B. F. (2024) · Diabetes Care · doi:10.2337/dci24-0001 · Cited by 32
Diabetes and obesity: leveraging heterogeneity for precision medicine
Franks, P. W., & Sargent, J. L. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae746 · Cited by 27
Self-citationImmunometabolic Interactions in Obesity: Implications for Therapeutic Strategies
Fei, Q., Huang, J., He, Y., Zhang, Y., Zhang, X., Wang, J., & Fu, Q. (2025) · Biomedicines · doi:10.3390/biomedicines13061429 · Cited by 32
“The complexity of obesity necessitates comprehensive treatment strategies that integrate immunomodulatory therapies with existing pharmacotherapies, such as metformin and GLP-1 receptor agonists, known for their efficacy in managing obesity and its metabolic consequences [124,125].”
Healthy decisions in the cued-attribute food choice paradigm have high test-retest reliability
Barakchian, Z., Beharelle, A. R., & Hare, T. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-91933-6 · Cited by 30
Buchanan, A., & Villani, A. M. (2021) · Healthcare · doi:10.3390/healthcare9101255 · Cited by 28
“In the present study, we also did not consider the use and/or impact of oral hypoglycaemic agents, such as metformin, on changes in body composition, which have been shown in clinical trials to facilitate weight loss [83].”
BackgroundCardiometabolic effects of SGLT2 inhibitors on polycystic ovary syndrome
Lempesis, I. G., Apple, S. J., Duarte, G., Palaiodimos, L., Kalaitzopoulos, D. R., Dalamaga, Μ., & Kokkinidis, D. G. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3682 · Cited by 25
“Studies have shown that the weight loss properties of metformin are secondary to its side effects and not to the modification of metabolic pathways.(98)”
BackgroundTondt, J., & Bays, H. E. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100017 · Cited by 24
“…reduce hunger via multifactorial effects such as enhancing the effects of gastrointestinal hormones applicable to weight loss (e.g., increased glucagon-like peptide-1 levels and receptors, increased peptide YY, decreased neuropeptide Y), all of which may facilitate long-term weight loss [57 – 59].”
BackgroundCacciatore, S., Gava, G., Calvani, R., Marzetti, E., Coelho‐Júnior, H. J., Picca, A., Esposito, I., Ciciarello, F., Salini, S., Russo, A., et al. (2023) · Nutrients · doi:10.3390/nu15234892 · Cited by 26
“Finally, the health benefits associated with the Medi-Diet are believed to be conveyed by a combination of nutritional factors as well as lifestyle and sociocultural influences, including engaging in regular physical activity, adequate rest, and conviviality [89].”
BackgroundThe Effects of Laparoscopic Sleeve Gastrectomy on the Parameters of Leptin Resistance in Obesity
Mazahreh, T. S., Alfaqih, M. A., Saadeh, R., Al-Zoubi, N. A., Hatamleh, M., Alqudah, A., Aleshawi, A. J., & Alzoubi, A. (2019) · Biomolecules · doi:10.3390/biom9100533 · Cited by 26
“Examples are (a) lifestyle modifications with dietary, exercise, and behavioral components [24], (b) pharmacological interventions [25], and (c) surgical interventions [26,27].”
BackgroundAbizadeh, M., Novin, M. G., Amidi, F., Ziaei, S. A., Abdollahifar, M., & Nazarian, H. (2020) · Reproductive Sciences · doi:10.1007/s43032-020-00168-9 · Cited by 22
Metformin effectively restores the HPA axis function in diet-induced obese rats
Shin, A. C., Balasubramanian, P., Suryadevara, P., Zyskowski, J., Herdt, T. H., MohanKumar, S. M. J., & MohanKumar, P. S. (2020) · International Journal of Obesity · doi:10.1038/s41366-020-00688-z · Cited by 19
“The ability of metformin to decrease weight gain, fat mass, and food consumption in DIO rats is supported by other studies [17, 20, 28, 47].”
ResultEating Disorders In weight-related Therapy (EDIT) Collaboration: rationale and study design
Lister, N. B., Baur, L. A., Paxton, S. J., Garnett, S. P., Ahern, A. L., Wilfley, D. E., Maguire, S., Sainsbury, A., Steinbeck, K. S., Braet, C., et al. (2023) · Nutrition Research Reviews · doi:10.1017/s0954422423000045 · Cited by 26
Nutritional Factors: Benefits in Glaucoma and Ophthalmologic Pathologies
Musa, M., Zeppieri, M., Atuanya, G. N., Enaholo, E. S., Topah, E. K., Ojo, O. M., & Salati, C. (2023) · Life · doi:10.3390/life13051120 · Cited by 22
“The weight loss-inducing effect [134] is also suggested to modulate cardiovascular risk factors among individuals with NIDDM.”
BackgroundLavoie-Gagne, O. Z., Lu, Y., MacLean, I. S., Forlenza, E. M., & Forsythe, B. (2020) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-20-00294 · Cited by 18
Weight Loss Outcomes With Telemedicine During COVID-19
Tchang, B. G., Morrison, C., Kim, J. T., Ahmed, F., Chan, K. M., Alonso, L. C., Aronne, L. J., & Shukla, A. P. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.793290 · Cited by 22
Long‐term weight loss maintenance with obesity pharmacotherapy: A retrospective cohort study
Tchang, B. G., Aras, M., Wu, A. H. B., Aronne, L. J., & Shukla, A. P. (2021) · Obesity Science & Practice · doi:10.1002/osp4.575 · Cited by 19
Metabolic disorders in prediabetes: From mechanisms to therapeutic management
Ping, W.-X., Hu, S., Su, J., & Ouyang, S. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i3.361 · Cited by 25
Gong, D., Chen, X., Yang, L., Zhang, Y., Zhong, Q., Liu, J., Yan, C., Cai, Y., Yang, W., & Wang, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1225696 · Cited by 19
Venditti, E. M., Marcus, M. D., Miller, R. G., Arena, V. C., Greenspan, S. L., & Rockette‐Wagner, B. (2020) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaa229 · Cited by 18
Self-citationRethinking the Goals of Diabetes Prevention Programs
Mezuk, B. R., & Allen, J. O. (2021) · Diabetes Care · doi:10.2337/dci21-0038 · Cited by 17
Pharmacologic Weight Management in the Era of Adolescent Obesity
Raman, V. S., Gupta, A., Ashraf, A. P., Breidbart, E., Gourgari, E., Kamboj, M. K., Kohn, B., Krishnan, S., Lahoti, A., Matlock, K. A., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac418 · Cited by 15
Weight Loss in Midlife, Chronic Disease Incidence, and All-Cause Mortality During Extended Follow-Up
Strandberg, T. E., Strandberg, A. Y., Jyväkorpi, S. K., Urtamo, A., Nyberg, S. T., Frank, P., Pentti, J., Pitkälä, K. H., & Mika Kivimaki, B. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.11825 · Cited by 20
The Effective Use of Anti-obesity Medications
Schmitz, S. H., & Aronne, L. J. (2023) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2023.08.003 · Cited by 13
Ruan, G., Yuan, S., Lou, A., Mo, Y., Qu, Y., Guo, D., Guan, S., Zhang, Y., Lan, X., Luo, J. F., et al. (2022) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-022-05434-2 · Cited by 14
“Metformin has been shown to have a weight-losing effect [12], which could also explain the potential OAprotective effect.”
BackgroundDiabetes mellitus in Bardet Biedl syndrome
Pomeroy, J. J., Offenwanger, K.-M., & Timmler, T. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000788 · Cited by 15
Ferrannini, G., Pollock, C. A., Natali, A., Yavin, Y., Mahaffey, K. W., & Ferrannini, E. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01832-5 · Cited by 12
“In most patients with type 2 diabetes, chronic insulin treatment and use of sulphonylureas induce weight gain [16, 17], while metformin treatment has been consistently associated with modest weight loss [18, 19].”
BackgroundJha, K. K., Adhikari, R., Tasdighi, E., Osuji, N., Rajan, T., & Blaha, M. J. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01066-y · Cited by 13
Handelsman, D. J., Grossmann, M., Yeap, B. B., Stuckey, B. G. A., Shankara‐Narayana, N., Conway, A. J., Inder, W. J., McLachlan, R. I., Allan, C. A., Jenkins, A. J., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad485 · Cited by 12
Khosroshahi, M. Z., Asbaghi, O., Moradi, S., Kelishadi, M. R., Kaviani, M., Mardani, M., & Jalili, C. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.104022 · Cited by 12
Pourfarzi, F., Rezaei, S., Moghadam, T. Z., Zandian, H., & Dibazar, F. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01096-2 · Cited by 15
“Moreover, taking diabetic medications can lead to weight-loss in diabetics [43].”
BackgroundShould I consider metformin therapy for weight loss in patients with obesity but without diabetes?
Rodriguez, P., Pantalone, K. M., Griebeler, M. L., & Burguera, B. G. (2023) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.90a.22096 · Cited by 9
Perspectives on Prediabetes and Aging
Al‐Sofiani, M. E., Asiri, A. A., Alajmi, S., & Alkeridy, W. A. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.10.011 · Cited by 11
An update on pharmacotherapeutic strategies for obesity
Tchang, B. G., Tarazi, M. S., Aras, M., & Shukla, A. P. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1888927 · Cited by 12
Davis, J. P. E., Reticker, A., Han, H. H., Orandi, B. J., Henry, Z. H., Tsunoda, S. M., Heimbach, J. K., Schulman, A. R., Tincopa, M. A., & the AST LICOP Controversies Conference Working Group (2025) · Liver Transplantation · doi:10.1097/lvt.0000000000000645 · Cited by 8
Langan, A., Bader, A., Goedkoop, S., Cummings, S., Tsikitas, M., Nogueira, I., Reyes, K. J. C., & Stanford, F. C. (2020) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2020.10.002 · Cited by 9
Status of Nutrition In Hemodialysis Patients Survey (SNIPS): Malnutrition risk by diabetes status
Boaz, M., Azoulay, O., Shriqui, V. K., & Weinstein, T. (2021) · Diabetic Medicine · doi:10.1111/dme.14543 · Cited by 14
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
The dual burden of obesity: decoding metabolism and female reproductive endocrinology
Chen, Y., Wang, R., Zhang, N., & Xu, L. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2025.1627607 · Cited by 12
Cumulative BMI and incident prediabetes over 30 years of follow‐up: The CARDIA study
Schreiner, P. J., Bae, S., Allen, N. B., Liu, K., Reis, J. P., Wu, C. O., Ingram, K. H., Lloyd‐Jones, D. M., Lewis, C. E., & Rana, J. S. (2023) · Obesity · doi:10.1002/oby.23866 · Cited by 7
“Apolzan et al. [14], however, showed that for these same interventions, metformin led to the greatest sustained weight loss in those with ≥ 5% weight loss after 1 year.”
BackgroundTanaka, A., Shimabukuro, M., Teragawa, H., Okada, Y., Takamura, T., Taguchi, I., Toyoda, S., Tomiyama, H., Ueda, S., Higashi, Y., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01352-0 · Cited by 10
“reported recently that chronic metformin treatment was also effective for maintaining a reduction in BW over time in subjects with a high-risk of developing diabetes [36].”
BackgroundGrowth differentiation factor 15 as an emerging novel biomarker in SARS-CoV-2 infection
Parchwani, D. N., Dholariya, S. J., Katoch, C. D. S., & Singh, R. (2022) · World Journal of Methodology · doi:10.5662/wjm.v12.i5.438 · Cited by 6
Management of Medication-Induced Weight Gain
Barenbaum, S. R., Kumar, R. B., & Aronne, L. J. (2023) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2023.08.006 · Cited by 6
The effect of metformin on cardiovascular markers in female mice consuming a high fat diet
de Alwis, N., Binder, N. K., Mangwiro, Y. T. M., Pritchard, N., Beard, S., Kaitu’u‐Lino, T. J., Brownfoot, F., & Hannan, N. J. (2022) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2022.10.006 · Cited by 6
Pfammatter, A. F., Battalio, S. L., Olvera, C., Dezelar, M., Moore, D., Scanlan, L., Siddique, J., Spring, B. J., & Chang, S. (2022) · Contemporary Clinical Trials · doi:10.1016/j.cct.2022.106750 · Cited by 6
Васильевна, Ц. О., Evdokimova, N. E., Васильевна, В. В., Latyntseva, L. D., & As, A. (2022) · Diabetes Mellitus · doi:10.14341/dm12916 · Cited by 9
Tanumihardjo, J. P., Davis, H., Zhu, M., On, H., Guillory, K. K., & Christensen, J. (2023) · Nutrients · doi:10.3390/nu15204368 · Cited by 8
“In both cases though, reductions did not meet increments (e.g., 5% weight loss, ≥ 50% LDL reduction) that could be clinically relevant [41,42].”
BackgroundA phenotypic approach to obesity treatment
Zandvakili, I., Pulaski, M., & Pickett‐Blakely, O. (2023) · Nutrition in Clinical Practice · doi:10.1002/ncp.11013 · Cited by 8
Factors involved in body weight loss and its maintenance in morbidly obese inpatients
Tadokoro, R., Iida, T., Mikura, K., Imai, H., Murai, N., Kaji, M., Hashizume, M., Kigawa, Y., Endo, K., Iizaka, T., et al. (2019) · Diabetology International · doi:10.1007/s13340-019-00403-y · Cited by 5
Ameer, F., Villacres, N. Y., Bustos, D., Shah, P., Appah, N., Luzaya, G. N., Corradi, F., Bakare, I. S., Trujillo, J. V., Mylavarapu, M., et al. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01770-x · Cited by 5
“…to metformin, placebo, or intensive lifestyle intervention, the mean weight loss at 15 years of follow-up was 6.2% for metformin, 3.7% for intensive lifestyle intervention, and 2.8% for placebo [82] This result highlighted the need for appropriate lifestyle interventions in weight management.”
InfluentialMetabolic and appetitive regulation of adipocyte mass during treatment of obesity
Purnell, J. Q., & le Roux, C. W. (2025) · Journal of Internal Medicine · doi:10.1111/joim.70045 · Cited by 10
“Despite these averages, there were a smaller number of patients who achieved and maintained more substantial weight loss [60].”
Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes
Salive, M. E., Tjaden, A. H., Ames, J. R., Crandall, J. P., Dabelea, D., Hazuda, H. P., Heckman‐Stoddard, B. M., Huckfeldt, P. J., Kuo, S., Strotmeyer, E. S., et al. (2026) · JAMA · doi:10.1001/jama.2026.8492 · Cited by 7
Self-citationCollins, C., McCallum, E., Nordby, K., Aggarwal, S., Griffith, E. H., Thomas, C., & Dunn, C. (2023) · Diabetology · doi:10.3390/diabetology4040051 · Cited by 4
Higher mitochondrial DNA copy number is associated with metformin-induced weight loss
Wang, J., Liang, H., Huang, R., Weng, X., Zheng, L., Wang, Y., Zheng, X., Gu, Z., Chen, F., Shao, J., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00258-0 · Cited by 6
Rani, N., Kaushik, A., Kardam, S., Kag, S., Raj, V. S., Ambasta, R. K., & Kumar, P. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.03.029 · Cited by 5
Hurst, T. E., McEwen, L. N., Joiner, K. L., & Herman, W. H. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002468 · Cited by 4
Potential of nutrition in body weight improvement in type 2 diabetes
Олеговна, Е. С., & Drapkina, O. M. (2023) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2023-3607 · Cited by 5
Lac-Phe mediates the anti-obesity effect of metforminPreprint
Xiao, S., Li, V. L., Lyu, X., Chen, X., Wei, W., Abbasi, F., Knowles, J. W., Deng, S., Tiwari, G., Shi, X., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.02.565321 · Cited by 4
“Beyond sprint exercise, little is known about pharmacological or physiologic stimuli that increase circulating Lac-Phe levels.”
BackgroundNon-oncologic to oncologic drug: A systematic review of drug repurposing in cancer
Dhanush, Y., & Ganesh, V. S. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04822-4 · Cited by 5
Metadata
- Authors
- Apolzan, J. W., Venditti, E. M., Edelstein, S. L., Knowler, W. C., Dabelea, D., Boyko, E. J., Pi-Sunyer, X., Kalyani, R. R., Franks, P. W., Srikanthan, P., Gadde, K. M., & for the Diabetes Prevention Program Research Group*
- Affiliations
- Pennington Biomedical Research Center (US)
- University of Pittsburgh Medical Center (US)
- George Washington University (US)
- National Institute of Diabetes and Digestive and Kidney Diseases (US)
- Colorado School of Public Health (US)
- VA Puget Sound Health Care System (US)
- Columbia University College of Physicians and Surgeons, New York, New York (X.P.)
- Johns Hopkins University (US)
- Lund University (SE)
- University of California, Los Angeles (US)
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2019-05-21
- Volume
- 170
- Issue
- 10
- Pages
- 682-690
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- PMC
- PMC6829283
- OpenAlex
- W2942237347
- Semantic Scholar
- e07c5f43b88902ef91823985e00f3f37893ea00e
- Cited by
- 156
- References
- 58
- Citations by year
- 2026: 19 · 2025: 20 · 2024: 21 · 2023: 28 · 2022: 22 · 2021: 21 · 2020: 16 · 2019: 9
- FWCI
- 13.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK048489)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- long-term weight loss, metformin, intensive lifestyle intervention, prediabetes, type 2 diabetes prevention, fasting blood glucose, age, family history of diabetes, Diabetes Prevention Program Outcomes Study
- MeSH terms
- Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Life Style, Male, Metformin, Middle Aged, United States, Weight Loss
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.